Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Marinus J. C. Eijkemans"'
Autor:
Eva S. van Marion, Esther B. Baart, Margarida Santos, Linette van Duijn, Evert J. P. van Santbrink, Régine P. M. Steegers-Theunissen, Joop S. E. Laven, Marinus J. C. Eijkemans
Publikováno v:
Reproductive Biology and Endocrinology, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background The predictive capability of time-lapse monitoring (TLM) selection algorithms is influenced by patient characteristics, type and quality of data included in the analysis and the used statistical methods. Previous studies excluded
Externí odkaz:
https://doaj.org/article/ff9225e5a0f64685a6ebc6ad6ac8427d
Autor:
Wouter A. C. van Amsterdam, Joost. J. C. Verhoeff, Netanja I. Harlianto, Gijs A. Bartholomeus, Aahlad Manas Puli, Pim A. de Jong, Tim Leiner, Anne S. R. van Lindert, Marinus J. C. Eijkemans, Rajesh Ranganath
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Randomized Controlled Trials (RCT) are the gold standard for estimating treatment effects but some important situations in cancer care require treatment effect estimates from observational data. We developed “Proxy based individual treatme
Externí odkaz:
https://doaj.org/article/a68451c10dc24dd393e8a5690b3bba25
Autor:
Noel Patson, Mavuto Mukaka, Lawrence Kazembe, Marinus J. C. Eijkemans, Don Mathanga, Miriam K. Laufer, Tobias Chirwa
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-14 (2022)
Abstract Background In preventive drug trials such as intermittent preventive treatment for malaria prevention during pregnancy (IPTp), where there is repeated treatment administration, recurrence of adverse events (AEs) is expected. Challenges in mo
Externí odkaz:
https://doaj.org/article/8f68c07440744fc8acb55beab37cc016
Autor:
Noel Patson, Mavuto Mukaka, Kennedy N. Otwombe, Lawrence Kazembe, Don P. Mathanga, Victor Mwapasa, Alinune N. Kabaghe, Marinus J. C. Eijkemans, Miriam K. Laufer, Tobias Chirwa
Publikováno v:
Malaria Journal, Vol 19, Iss 1, Pp 1-11 (2020)
Abstract Background Drug safety assessments in clinical trials present unique analytical challenges. Some of these include adjusting for individual follow-up time, repeated measurements of multiple outcomes and missing data among others. Furthermore,
Externí odkaz:
https://doaj.org/article/ec446955dac6432bbbe8856e27f62786
Publikováno v:
BMC Bioinformatics, Vol 18, Iss 1, Pp 1-11 (2017)
Abstract Background Aggregating gene expression data across experiments via meta-analysis is expected to increase the precision of the effect estimates and to increase the statistical power to detect a certain fold change. This study evaluates the po
Externí odkaz:
https://doaj.org/article/3cae4b83d1144df3bf30ba0699124658
Autor:
Maarten van Smeden, Joris A. H. de Groot, Karel G. M. Moons, Gary S. Collins, Douglas G. Altman, Marinus J. C. Eijkemans, Johannes B. Reitsma
Publikováno v:
BMC Medical Research Methodology, Vol 16, Iss 1, Pp 1-12 (2016)
Abstract Background Ten events per variable (EPV) is a widely advocated minimal criterion for sample size considerations in logistic regression analysis. Of three previous simulation studies that examined this minimal EPV criterion only one supports
Externí odkaz:
https://doaj.org/article/21370be43816498cbb234e85760efc97
Autor:
Putri W. Novianti, Ingeborg van der Tweel, Victor L. Jong, Kit C. B. Roes, Marinus J. C. Eijkemans
Publikováno v:
Cancer Informatics, Vol 2015, Iss Suppl. 5, Pp 1-10 (2015)
Externí odkaz:
https://doaj.org/article/1fdbaf63cbf74377afe1d9d503353d86
Autor:
Danya, Muilwijk, Domenique D, Zomer-van Ommen, Vincent A M, Gulmans, Marinus J C, Eijkemans, Cornelis K, van der Ent
Publikováno v:
ERJ open research. 8(4)
Although short-term efficacy of lumacaftor/ivacaftor and tezacaftor/ivacaftor is clearly established in clinical trials, data on long-term effectiveness is limited. This registry-based cohort study assessed real-world longitudinal outcomes of F508del
Autor:
René S Kahn, Inge Winter van Rossum, Stefan Leucht, Philip McGuire, Shon W Lewis, Marion Leboyer, Celso Arango, Paola Dazzan, Richard Drake, Stephan Heres, Covadonga M Díaz-Caneja, Dan Rujescu, Mark Weiser, Silvana Galderisi, Birte Glenthøj, Marinus J C Eijkemans, W Wolfgang Fleischhacker, Shitij Kapur, Iris E Sommer, Inge Winter-van Rossum, Metten Somers, Paula C Ywema, Shitisj Kapur, Andreas Meyer-Lindenberg, Wolfgang W Fleischhacker, Anne Lotte Meijering, Jocelyn Petter, Resy Van de Brug, Joost Schotsman, Jildou Zwerver, Jos Peuskens, Marc De Hert, Erik Thys, Lucho G Hranov, Valentin Hranov, Jan Libiger, Richard Köhler, Pavel Mohr, Birte Glenthoj, Brian Broberg, Signe Düring, Lone Baandrup, Stephane Jamain, Ina Giegling, Mor Bar Heim, Michael Davidson, Paola Bucci, Armida Mucci, Janusz Rybakowski, Agnieszka Remlinger-Molenda, Ilan Gonen, Paull Radu, Marina Díaz-Marsá, Alberto Rodriguez, Tomas Palomo, Roberto Rodriguez-Jimenez, Paz García-Portilla, Miquel Bernardo, Julio Bobes, Christina Vilares Oliveira, Gregor Berger, Claudia Wildt, Roccio Perez-Iglesias, Sarah Gregory, Danielle Wilson
Publikováno v:
The Lancet Psychiatry, 5(10), 797. Elsevier Limited
McGuire, P & Dazzan, P 2018, ' Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE) : a three-phase switching study ', The lancet. Psychiatry, vol. 5, no. 10, pp. 797-807 . https://doi.org/10.1016/S2215-0366(18)30252-9
The Lancet. Psychiatry, 5(10), 797-807. ELSEVIER SCI LTD
McGuire, P & Dazzan, P 2018, ' Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE) : a three-phase switching study ', The lancet. Psychiatry, vol. 5, no. 10, pp. 797-807 . https://doi.org/10.1016/S2215-0366(18)30252-9
The Lancet. Psychiatry, 5(10), 797-807. ELSEVIER SCI LTD
BACKGROUND: No established treatment algorithm exists for patients with schizophrenia. Whether switching antipsychotics or early use of clozapine improves outcome in (first-episode) schizophrenia is unknown.METHODS: This three-phase study was done in
Autor:
Antoni, Bayés-Genis, David E, Lanfear, Maurice W J, de Ronde, Josep, Lupón, Joost J, Leenders, Zhen, Liu, Nicolaas P A, Zuithoff, Marinus J C, Eijkemans, Elisabet, Zamora, Marta, De Antonio, Aeilko H, Zwinderman, Sara-Joan, Pinto-Sietsma, Yigal M, Pinto
Publikováno v:
European journal of heart failure. 20(1)
Small studies suggested circulating microRNAs (miRNAs) as biomarkers for heart failure (HF). However, standardized approaches and quality assessment for measuring circulating miRNAs are not uniformly established, and most studies have been small, so